Lipocine Inc (LPCN)
NASDAQ:LPCN
Want to see LPCN full AI Analyst Report?
LPCN Stock Chart & Stats
$2.92
-$0.05(-1.04%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.04%)
Day’s Range― - ―
52-Week Range$1.81 - $12.37
Previous CloseN/A
Volume16.76K
Average Volume (3M)108.73K
Market Cap
$19.21M
Enterprise Value$8.56M
Total Cash (Recent Filing)$24.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Aug 06, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding8,244,253
10 Day Avg. Volume134,368
30 Day Avg. Volume108,728
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.02
Price to Sales (P/S)22.14
P/FCF Ratio-4.48
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue4.28
Enterprise Value/Gross Profit-52.11
Enterprise Value/Ebitda-0.75
Forecast
1Y Price Target
$6.00Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$650.00K
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetZero reported debt and materially improved equity provide durable financial flexibility to fund near-term development choices, support regulatory interactions, and pursue partnering or strategic alternatives without immediate leverage pressure, reducing refinancing risk over months.
Proprietary Oral Drug Delivery CapabilityOwnership of Lip'ral oral delivery technology and focus on converting known molecules to oral forms is a sustainable competitive asset, enabling differentiated product profiles, potential licensing or partnering, and long-term market applicability across endocrine and CNS indications.
Clinical Program Visibility And Scientific EngagementRepeated scientific presentations and KOL outreach signal credible clinical development momentum and external validation. These durable activities improve chances for regulatory dialogue, targeted follow-up studies, and partnerships, supporting long-term program value even after mixed topline results.
Bears Say
Negative Operating Cash Flow / Cash BurnSustained negative operating and free cash flow creates ongoing funding dependence. Over a multi-month horizon this elevates dilution or financing risk, constrains the ability to execute development programs internally, and limits optionality absent new capital or partnerships.
Persistent Unprofitable Operations And Volatile RevenueSmall, volatile revenue combined with materially negative gross profit and large operating losses indicate the business cannot self-fund development. This structural mismatch pressures margins and returns, making multi-month sustainability contingent on external financing or strategic transactions.
Clinical Program Uncertainty After Phase 3 MissA failed overall Phase 3 primary endpoint creates durable execution risk: regulatory path, need for additional validation, or pivoting to niche indications. Reliance on subgroup analyses complicates approvals and partnering, materially affecting long-term commercialization prospects.
Lipocine News
LPCN FAQ
What was Lipocine Inc’s price range in the past 12 months?
Lipocine Inc lowest stock price was $1.81 and its highest was $12.37 in the past 12 months.
What is Lipocine Inc’s market cap?
Lipocine Inc’s market cap is $19.21M.
When is Lipocine Inc’s upcoming earnings report date?
Lipocine Inc’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Lipocine Inc’s earnings last quarter?
Lipocine Inc released its earnings results on May 07, 2026. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.485 by -$0.055.
Is Lipocine Inc overvalued?
According to Wall Street analysts Lipocine Inc’s price is currently Undervalued.
Does Lipocine Inc pay dividends?
Lipocine Inc does not currently pay dividends.
What is Lipocine Inc’s EPS estimate?
Lipocine Inc’s EPS estimate is -0.44.
How many shares outstanding does Lipocine Inc have?
Lipocine Inc has 8,244,253 shares outstanding.
What happened to Lipocine Inc’s price movement after its last earnings report?
Lipocine Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.485. Following the earnings report the stock price went down -0.837%.
Which hedge fund is a major shareholder of Lipocine Inc?
Currently, no hedge funds are holding shares in LPCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lipocine Inc
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement. The company's development pipeline also encompasses several other promising candidates: LPCN 1144: An orally administered prodrug derived from bioidentical testosterone, which has successfully completed Phase II clinical trials for the treatment of non-cirrhotic non-alcoholic steatohepatitis. LPCN 1111: An oral prodrug of testosterone tridecanoate, engineered for once-daily administration, and having also concluded Phase II clinical studies in men experiencing hypogonadism. LPCN 1148: A novel prodrug combining testosterone and testosterone laurate, designed for the management of decompensated cirrhosis. LPCN 1154: An investigational new drug application has been submitted to initiate a Phase 2 study targeting Postpartum Depression. LPCN 2101: A compound intended for women with epilepsy, which has progressed beyond its pre-clinical study phase. LPCN 1107: An oral hydroxyprogesterone caproate product, which has completed its dose-finding Phase II clinical trial aimed at preventing recurrent preterm birth. The corporate headquarters for Lipocine Inc. are located in Salt Lake City, Utah.
LPCN Stock 12 Month Forecast
Average Price Target
$6.00
▲(105.48% Upside)
Technical Analysis
Ownership Overview
4.61% Insiders
3.10% Mutual Funds
28.41% Other Institutional Investors
61.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---